Arrrhythmia Research Technology sees drop in net income for Q3

Arrhythmia Research Technology (ART), and its wholly owned subsidiary Micron Products, has reported decreased earnings for the 2008 third quarter.

The Fitchburg, Mass.-based company booked total revenue of $5.84 million and a net income of $68,000 for the quarter ended Sept. 30, compared to total revenue of $4.46 million and net income of $421,000 for the same quarter of 2007.

Based on these results, ART saw total revenue increase 31 percent while net income decreased by 84 percent in the quarter ending Sept. 30, as compared to the same period in 2007. 

“The decrease in net income during the quarter was the result of several factors. We experienced lower than expected margins in our sensor products as a result of continued price erosion due to a competitive marketplace as well as volatility in commodity prices which resulted in higher material costs that we were unable to completely offset with price increases to customers. The MIT division incurred higher labor costs to meet customer delivery schedules in addition to capital equipment investments associated with early stage products. Revenues from these early stage products are not expected to offset operating costs positively until 2009,” said James E. Rouse, ART’s president and CEO.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.